ASN-007 is under clinical development by Erasca and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASN-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ASN-007 is under development for the treatment of advanced or metastatic solid tumors including melanoma, colorectal cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma. The drug candidate acts by targeting RAS/MEK/ERK signaling pathway that is upregulated in a wide variety of tumors, by direct inhibition of extracellular signal-regulated kinases (ERK 1/2). It is administered through oral route.
It was also under development for the treatment of myelodysplastic syndrome and hematological malignancies including relapsed and refractory acute myeloid leukemia.
Erasca is an oncology drug development company that uses its artificial intelligence drug discovery platform to treat and cure cancer. The company is headquartered in San Diego, California, the US.
For a complete picture of ASN-007’s drug-specific PTSR and LoA scores, buy the report here.